title: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue.
abstract: BACKGROUND
  We previously reported that caffeine-potentiated chemotherapy induced significantly good response in patients with musculoskeletal sarcomas. In that series, patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  
  
  METHODS
  Five patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  
  
  RESULTS
  Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer. Good responses (gross tumor shrinkage >30%, or histologically >90% necrosis) to chemotherapy were seen in all five patients. Survival time was >1 year in all patients, and three out of five patients presented no evidence of local recurrence or metastasis at the final follow-up.
  
  
  CONCLUSIONS
  Caffeine-potentiated chemotherapy may be of benefit for malignant tumors other than musculoskeletal sarcoma.
authors.affiliation: Department of Orthopaedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hayashi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tsuchiya
authors.forename: Norio
authors.initials: N
authors.lastname: Yamamoto
authors.forename: Michiaki
authors.initials: M
authors.lastname: Karita
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Shirai
authors.forename: Hideji
authors.initials: H
authors.lastname: Nishida
authors.forename: Akihiko
authors.initials: A
authors.lastname: Takeuchi
authors.forename: Katsuro
authors.initials: K
authors.lastname: Tomita
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D002110:Caffeine / Q000008:administration & dosage / Q000494:pharmacology*; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary; D004357:Drug Synergism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000556:secondary; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000473:pathology; D014625:Vaginal Neoplasms / Q000188:drug therapy / Q000473:pathology
chemical_list: D002110:Caffeine